Mast cell stabilizers treatment for systemic disorders
First Claim
1. A method of administering a therapeutically effective amount of cromolyn sodium to a patient in need thereof, comprising administering to said patient an aqueous pharmaceutical composition consisting of (i) from about 2% to about 6% by weight of cromolyn sodium and (ii) an osmolarity adjusting agent consisting of (A) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (B) optionally salts of EDTA, wherein said pharmaceutical composition is administered to said patient by inhalation into the lungs in the form of an aerosol exhibiting a respirable fraction (≤
- 5 μ
m) as measured by USP <
1601>
of at least about 60%.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.
132 Citations
20 Claims
-
1. A method of administering a therapeutically effective amount of cromolyn sodium to a patient in need thereof, comprising administering to said patient an aqueous pharmaceutical composition consisting of (i) from about 2% to about 6% by weight of cromolyn sodium and (ii) an osmolarity adjusting agent consisting of (A) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (B) optionally salts of EDTA, wherein said pharmaceutical composition is administered to said patient by inhalation into the lungs in the form of an aerosol exhibiting a respirable fraction (≤
- 5 μ
m) as measured by USP <
1601>
of at least about 60%. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
- 5 μ
-
10. A method of administering a therapeutically effective amount of cromolyn sodium to a patient in need thereof, comprising administering to said patient an aqueous pharmaceutical composition comprising (i) from about 2% to about 6% by weight of cromolyn sodium, inclusive of endpoints, and (ii) an osmolarity adjusting agent consisting of (A) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (B) salts of EDTA, wherein said pharmaceutical composition is administered to said patient by inhalation into the lungs in the form of an aerosol exhibiting a respirable fraction (≤
- 5 μ
m) as measured by USP <
1601>
of at least about 60%. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- 5 μ
Specification